Fulvestrant for the treatment of advanced breast cancer. Issue 7 (3rd July 2018)

• Record Type: Journal Article
• Authors: Blackburn, Sophie A.; Parks, Ruth M.; Cheung, Kwok-Leung
• Is Part Of: Expert review of anticancer therapy. Volume 18:Issue 7(2018)
• Page Start: 619
• Page End: 628
• Publication Date: 2018-07-03
• Subjects: Fulvestrant -- advanced breast cancer -- endocrine therapy -- pure anti-oestrogen; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2018.1473038
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction : The current issues with endocrine therapy for treatment of advanced breast cancer include balance of efficacy of therapy versus tolerability as well as hormone resistance. The efficacy of fulvestrant, a selective oestrogen receptor degrader (SERD), has been demonstrated in hormone receptor positive patients previously untreated or treated with hormonal therapy. Areas covered : This article discusses the journey of fulvestrant licensing, its efficacy in combination with other endocrine therapies and the future role it may have within breast cancer treatment. Expert commentary : Within phase III trials, fulvestrant has demonstrated equivalent or improved clinical efficacy when compared with established endocrine agents. In the recent decade, fulvestrant has achieved licensing as a second line agent in non-operative advanced breast cancer at initially 250mg, increasing to 500mg. Presently, fulvestrant is licensed globally as first line endocrine management for advanced breast cancer in post-menopausal women. Early combination trials of fulvestrant and cyclin dependent kinase 4/6 inhibitors have demonstrated good clinical efficacy with improved progression free survival when compared to fulvestrant alone.